1
|
Sasu BJ, Opiteck GJ, Gopalakrishnan S, Kaimal V, Furmanak T, Huang D, Goswami A, He Y, Chen J, Nguyen A, Balakumaran A, Shah NN, Hamadani M, Bone KM, Prashad S, Bowen MA, Pertel T, Embree HD, Gidwani SG, Chang D, Moore A, Leonard M, Amado RG. Detection of chromosomal alteration after infusion of gene-edited allogeneic CAR T cells. Mol Ther 2023; 31:676-685. [PMID: 36518079 PMCID: PMC10014221 DOI: 10.1016/j.ymthe.2022.12.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2022] [Revised: 11/18/2022] [Accepted: 12/09/2022] [Indexed: 12/15/2022] Open
Abstract
A chromosome 14 inversion was found in a patient who developed bone marrow aplasia following treatment with allogeneic chimeric antigen receptor (CAR) Tcells containing gene edits made with transcription activator-like effector nucleases (TALEN). TALEN editing sites were not involved at either breakpoint. Recombination signal sequences (RSSs) were found suggesting recombination-activating gene (RAG)-mediated activity. The inversion represented a dominant clone detected in the context of decreasing absolute CAR Tcell and overall lymphocyte counts. The inversion was not associated with clinical consequences and wasnot detected in the drug product administered to this patient or in any drug product used in this or other trials using the same manufacturing processes. Neither was the inversion detected in this patient at earlier time points or in any other patient enrolled in this or other trials treated with this or other product lots. This case illustrates that spontaneous, possibly RAG-mediated, recombination events unrelated to gene editing can occur in adoptive cell therapy studies, emphasizes the need for ruling out off-target gene editing sites, and illustrates that other processes, such as spontaneous V(D)J recombination, can lead to chromosomal alterations in infused cells independent of gene editing.
Collapse
Affiliation(s)
- Barbra J Sasu
- Allogene Therapeutics, South San Francisco, CA 94080, USA
| | | | | | - Vivek Kaimal
- Allogene Therapeutics, South San Francisco, CA 94080, USA
| | - Tom Furmanak
- Allogene Therapeutics, South San Francisco, CA 94080, USA
| | - David Huang
- Allogene Therapeutics, South San Francisco, CA 94080, USA
| | | | - Ying He
- Allogene Therapeutics, South San Francisco, CA 94080, USA
| | - Jiamin Chen
- Allogene Therapeutics, South San Francisco, CA 94080, USA
| | - Anh Nguyen
- Allogene Therapeutics, South San Francisco, CA 94080, USA
| | | | - Nirav N Shah
- Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI 53226, USA
| | - Mehdi Hamadani
- Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI 53226, USA
| | - Kathleen M Bone
- Department of Pathology, Medical College of Wisconsin, Milwaukee, WI 53226, USA
| | - Sacha Prashad
- Allogene Therapeutics, South San Francisco, CA 94080, USA
| | | | - Thomas Pertel
- Allogene Therapeutics, South San Francisco, CA 94080, USA
| | | | | | - David Chang
- Allogene Therapeutics, South San Francisco, CA 94080, USA
| | - Alison Moore
- Allogene Therapeutics, South San Francisco, CA 94080, USA
| | - Mark Leonard
- Allogene Therapeutics, South San Francisco, CA 94080, USA
| | - Rafael G Amado
- Allogene Therapeutics, South San Francisco, CA 94080, USA.
| |
Collapse
|
2
|
Wang X, Hefton A, Ni K, Ukadike KC, Bowen MA, Eckert M, Stevens A, Lood C, Mustelin T. Autoantibodies Against Unmodified and Citrullinated Human Endogenous Retrovirus K Envelope Protein in Patients With Rheumatoid Arthritis. J Rheumatol Suppl 2022; 49:26-35. [PMID: 34334364 PMCID: PMC8963793 DOI: 10.3899/jrheum.201492] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/16/2021] [Indexed: 01/03/2023]
Abstract
OBJECTIVE Autoantibodies against proteins encoded by human endogenous retrovirus K (HERV-K) have been reported in patients with rheumatoid arthritis (RA), but their relevance, if any, has remained unresolved. We revisited this question and tested if such autoantibodies may react with citrullinated epitopes on the envelope (Env) protein of HERV-K. METHODS Immunoblotting and ELISAs were conducted with unmodified Env protein and with Env citrullinated by protein arginine deiminase 4 (PAD4). Sera from 100 patients with RA, plasma from 32 patients with juvenile idiopathic arthritis (JIA), and healthy adult and pediatric controls were included. Antibody reactivity was evaluated for correlations with clinical and laboratory variables of the patients. RESULTS We replicated and expanded upon published data suggesting that patients with RA or JIA have autoantibodies against HERV-K Env, some with high titers. Anti-HERV-K antibodies correlated with cigarette smoking and with circulating myeloperoxidase-DNA complexes indicative of nonapoptotic neutrophil cell death. Further, most of the patients with RA, but not those with JIA, had autoantibodies that reacted more strongly with Env that was citrullinated by PAD4. These anticitrullinated Env autoantibodies correlated with seropositivity and tended to be higher in patients with erosive disease. CONCLUSION Our data suggest that anti-HERV-K immunity is elevated in RA and JIA and may have a connection with pathogenic protein citrullination in RA.
Collapse
Affiliation(s)
- Xiaoxing Wang
- X. Wang, PhD, A. Hefton, K. Ni, BS, K.C. Ukadike, MD, Acting Instructor, C. Lood, PhD, Associate Professor, T. Mustelin, MD, PhD, Professor, Division of Rheumatology, Department of Medicine, University of Washington, Seattle, Washington
| | - Amanda Hefton
- X. Wang, PhD, A. Hefton, K. Ni, BS, K.C. Ukadike, MD, Acting Instructor, C. Lood, PhD, Associate Professor, T. Mustelin, MD, PhD, Professor, Division of Rheumatology, Department of Medicine, University of Washington, Seattle, Washington
| | - Kathryn Ni
- X. Wang, PhD, A. Hefton, K. Ni, BS, K.C. Ukadike, MD, Acting Instructor, C. Lood, PhD, Associate Professor, T. Mustelin, MD, PhD, Professor, Division of Rheumatology, Department of Medicine, University of Washington, Seattle, Washington
| | - Kennedy C. Ukadike
- X. Wang, PhD, A. Hefton, K. Ni, BS, K.C. Ukadike, MD, Acting Instructor, C. Lood, PhD, Associate Professor, T. Mustelin, MD, PhD, Professor, Division of Rheumatology, Department of Medicine, University of Washington, Seattle, Washington
| | - Michael A. Bowen
- M.A. Bowen, PhD, Product and Process Development, Allogene Therapeutics, San Francisco, California
| | - Mary Eckert
- M. Eckert, BS, Seattle Children’s Research Institute, Seattle, Washington
| | - Anne Stevens
- A. Stevens, MD, Professor, Seattle Children’s Research Institute, Seattle, Division of Rheumatology, Department of Pediatrics, University of Washington, Seattle, Washington, and Janssen Research & Development, LLC, Wayne, Pennsylvania, USA
| | - Christian Lood
- X. Wang, PhD, A. Hefton, K. Ni, BS, K.C. Ukadike, MD, Acting Instructor, C. Lood, PhD, Associate Professor, T. Mustelin, MD, PhD, Professor, Division of Rheumatology, Department of Medicine, University of Washington, Seattle, Washington
| | - Tomas Mustelin
- X. Wang, PhD, A. Hefton, K. Ni, BS, K.C. Ukadike, MD, Acting Instructor, C. Lood, PhD, Associate Professor, T. Mustelin, MD, PhD, Professor, Division of Rheumatology, Department of Medicine, University of Washington, Seattle, Washington
| |
Collapse
|
3
|
Chaerkady R, Zhou Y, Delmar JA, Weng SHS, Wang J, Awasthi S, Sims D, Bowen MA, Yu W, Cazares LH, Sims GP, Hess S. Characterization of Citrullination Sites in Neutrophils and Mast Cells Activated by Ionomycin via Integration of Mass Spectrometry and Machine Learning. J Proteome Res 2021; 20:3150-3164. [PMID: 34008986 DOI: 10.1021/acs.jproteome.1c00028] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Citrullination is an important post-translational modification implicated in many diseases including rheumatoid arthritis (RA), Alzheimer's disease, and cancer. Neutrophil and mast cells have different expression profiles for protein-arginine deiminases (PADs), and ionomycin-induced activation makes them an ideal cellular model to study proteins susceptible to citrullination. We performed high-resolution mass spectrometry and stringent data filtration to identify citrullination sites in neutrophil and mast cells treated with and without ionomycin. We identified a total of 833 validated citrullination sites on 395 proteins. Several of these citrullinated proteins are important components of pathways involved in innate immune responses. Using this benchmark primary sequence data set, we developed machine learning models to predict citrullination in neutrophil and mast cell proteins. We show that our models predict citrullination likelihood with 0.735 and 0.766 AUCs (area under the receiver operating characteristic curves), respectively, on independent validation sets. In summary, this study provides the largest number of validated citrullination sites in neutrophil and mast cell proteins. The use of our novel motif analysis approach to predict citrullination sites will facilitate the discovery of novel protein substrates of protein-arginine deiminases (PADs), which may be key to understanding immunopathologies of various diseases.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Michael A Bowen
- Antibody Discovery and Protein Engineering (ADPE), R&D AstraZeneca, Gaithersburg, Maryland 20878, United States
| | | | | | | | | |
Collapse
|
4
|
Roy G, Reier J, Garcia A, Martin T, Rice M, Wang J, Prophet M, Christie R, Dall'Acqua W, Ahuja S, Bowen MA, Marelli M. Development of a high yielding expression platform for the introduction of non-natural amino acids in protein sequences. MAbs 2021; 12:1684749. [PMID: 31775561 PMCID: PMC6927762 DOI: 10.1080/19420862.2019.1684749] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
The ability to genetically encode non-natural amino acids (nnAAs) into proteins offers an expanded tool set for protein engineering. nnAAs containing unique functional moieties have enabled the study of post-translational modifications, protein interactions, and protein folding. In addition, nnAAs have been developed that enable a variety of biorthogonal conjugation chemistries that allow precise and efficient protein conjugations. These are being studied to create the next generation of antibody-drug conjugates with improved efficacy, potency, and stability for the treatment of cancer. However, the efficiency of nnAA incorporation, and the productive yields of cell-based expression systems, have limited the utility and widespread use of this technology. We developed a process to isolate stable cell lines expressing a pyrrolysyl-tRNA synthetase/tRNApyl pair capable of efficient nnAA incorporation. Two different platform cell lines generated by these methods were used to produce IgG-expressing cell lines with normalized antibody titers of 3 g/L using continuous perfusion. We show that the antibodies produced by these platform cells contain the nnAA functionality that enables facile conjugations. Characterization of these highly active and robust platform hosts identified key parameters that affect nnAA incorporation efficiency. These highly efficient host platforms may help overcome the expression challenges that have impeded the developability of this technology for manufacturing proteins with nnAAs and represents an important step in expanding its utility.
Collapse
Affiliation(s)
- Gargi Roy
- Antibody Discovery and Protein Engineering, AstraZeneca, Gaithersburg, Maryland, USA
| | - Jason Reier
- Cell Culture and Fermentation Sciences, AstraZeneca, Gaithersburg, Maryland, USA
| | - Andrew Garcia
- Antibody Discovery and Protein Engineering, AstraZeneca, Gaithersburg, Maryland, USA
| | - Tom Martin
- Antibody Discovery and Protein Engineering, AstraZeneca, Gaithersburg, Maryland, USA
| | - Megan Rice
- Antibody Discovery and Protein Engineering, AstraZeneca, Gaithersburg, Maryland, USA
| | - Jihong Wang
- Analytical Sciences, AstraZeneca, Gaithersburg, Maryland, USA
| | - Meagan Prophet
- Analytical Sciences, AstraZeneca, Gaithersburg, Maryland, USA
| | - Ronald Christie
- Antibody Discovery and Protein Engineering, AstraZeneca, Gaithersburg, Maryland, USA
| | - William Dall'Acqua
- Antibody Discovery and Protein Engineering, AstraZeneca, Gaithersburg, Maryland, USA
| | - Sanjeev Ahuja
- Cell Culture and Fermentation Sciences, AstraZeneca, Gaithersburg, Maryland, USA
| | - Michael A Bowen
- Antibody Discovery and Protein Engineering, AstraZeneca, Gaithersburg, Maryland, USA
| | - Marcello Marelli
- Antibody Discovery and Protein Engineering, AstraZeneca, Gaithersburg, Maryland, USA
| |
Collapse
|
5
|
Li S, Cha SW, Heffner K, Hizal DB, Bowen MA, Chaerkady R, Cole RN, Tejwani V, Kaushik P, Henry M, Meleady P, Sharfstein ST, Betenbaugh MJ, Bafna V, Lewis NE. Proteogenomic Annotation of Chinese Hamsters Reveals Extensive Novel Translation Events and Endogenous Retroviral Elements. J Proteome Res 2019; 18:2433-2445. [PMID: 31020842 DOI: 10.1021/acs.jproteome.8b00935] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
A high-quality genome annotation greatly facilitates successful cell line engineering. Standard draft genome annotation pipelines are based largely on de novo gene prediction, homology, and RNA-Seq data. However, draft annotations can suffer from incorrect predictions of translated sequence, inaccurate splice isoforms, and missing genes. Here, we generated a draft annotation for the newly assembled Chinese hamster genome and used RNA-Seq, proteomics, and Ribo-Seq to experimentally annotate the genome. We identified 3529 new proteins compared to the hamster RefSeq protein annotation and 2256 novel translational events (e.g., alternative splices, mutations, and novel splices). Finally, we used this pipeline to identify the source of translated retroviruses contaminating recombinant products from Chinese hamster ovary (CHO) cell lines, including 119 type-C retroviruses, thus enabling future efforts to eliminate retroviruses to reduce the costs incurred with retroviral particle clearance. In summary, the improved annotation provides a more accurate resource for CHO cell line engineering, by facilitating the interpretation of omics data, defining of cellular pathways, and engineering of complex phenotypes.
Collapse
Affiliation(s)
| | | | | | - Deniz Baycin Hizal
- Antibody Discovery and Protein Engineering , AstraZeneca , Gaithersburg , Maryland , United States
| | - Michael A Bowen
- Antibody Discovery and Protein Engineering , AstraZeneca , Gaithersburg , Maryland , United States
| | - Raghothama Chaerkady
- Antibody Discovery and Protein Engineering , AstraZeneca , Gaithersburg , Maryland , United States
| | | | - Vijay Tejwani
- Colleges of Nanoscale Science and Engineering , SUNY Polytechnic Institute , Albany , New York 12203 , United States
| | - Prashant Kaushik
- National Institute for Cellular Biotechnology , Dublin City University , Dublin 9, Ireland
| | - Michael Henry
- National Institute for Cellular Biotechnology , Dublin City University , Dublin 9, Ireland
| | - Paula Meleady
- National Institute for Cellular Biotechnology , Dublin City University , Dublin 9, Ireland
| | - Susan T Sharfstein
- Colleges of Nanoscale Science and Engineering , SUNY Polytechnic Institute , Albany , New York 12203 , United States
| | | | | | | |
Collapse
|
6
|
Chakrabarti L, Zhuang L, Roy G, Bowen MA, Dall’Acqua WF, Hawley‐Nelson P, Marelli M. Amber suppression coupled with inducible surface display identifies cells with high recombinant protein productivity. Biotechnol Bioeng 2019; 116:793-804. [PMID: 30536645 PMCID: PMC6590230 DOI: 10.1002/bit.26892] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2018] [Accepted: 12/06/2018] [Indexed: 12/19/2022]
Abstract
Cell line development (CLD) for biotherapeutics is a time- and resource-intensive process requiring the isolation and screening of large numbers of clones to identify high producers. Novel methods aimed at enhancing cell line screening efficiency using markers predictive of productivity early in the CLD process are needed to reliably generate high-yielding cell lines. To enable efficient and selective isolation of antibody expressing Chinese hamster ovary cells by fluorescence-activated cell sorting, we developed a strategy for the expression of antibodies containing a switchable membrane-associated domain to anchor an antibody to the membrane of the expressing cell. The switchable nature of the membrane domain is governed by the function of an orthogonal aminoacyl transfer RNA synthetase/tRNApyl pair, which directs a nonnatural amino acid (nnAA) to an amber codon encoded between the antibody and the membrane anchor. The process is "switchable" in response to nnAA in the medium, enabling a rapid transition between the surface display and secretion. We demonstrate that the level of cell surface display correlates with productivity and provides a method for enriching phenotypically stable high-producer cells. The strategy provides a means for selecting high-producing cells with potential applications to multiple biotherapeutic protein formats.
Collapse
Affiliation(s)
- Lina Chakrabarti
- Cell Culture and Fermentation Science, MedImmuneGaithersburgMaryland
| | - Li Zhuang
- Antibody Discovery and Protein Engineering, MedImmuneGaithersburgMaryland
| | - Gargi Roy
- Antibody Discovery and Protein Engineering, MedImmuneGaithersburgMaryland
| | - Michael A. Bowen
- Antibody Discovery and Protein Engineering, MedImmuneGaithersburgMaryland
| | | | - Pam Hawley‐Nelson
- Cell Culture and Fermentation Science, MedImmuneGaithersburgMaryland
| | - Marcello Marelli
- Antibody Discovery and Protein Engineering, MedImmuneGaithersburgMaryland
| |
Collapse
|
7
|
Britton ZT, London TB, Carrell J, Dosanjh B, Wilkinson T, Bowen MA, Wu H, Dall’Acqua WF, Marelli M, Mazor Y. Tag-on-Demand: exploiting amber codon suppression technology for the enrichment of high-expressing membrane protein cell lines. Protein Eng Des Sel 2019; 31:389-398. [DOI: 10.1093/protein/gzy032] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2018] [Revised: 11/16/2018] [Accepted: 12/18/2018] [Indexed: 12/20/2022] Open
Affiliation(s)
- Zachary T Britton
- Antibody Discovery and Protein Engineering, MedImmune, Gaithersburg, MD, USA
| | - Timothy B London
- Antibody Discovery and Protein Engineering, MedImmune, Cambridge, UK
- Current affiliation: TC BioPharm Limited, Glasgow, UK
| | - Jeffrey Carrell
- Respiratory, Inflammation and Autoimmune, MedImmune, Gaithersburg, MD, USA
| | - Bhupinder Dosanjh
- Antibody Discovery and Protein Engineering, MedImmune, Cambridge, UK
| | - Trevor Wilkinson
- Antibody Discovery and Protein Engineering, MedImmune, Cambridge, UK
| | - Michael A Bowen
- Antibody Discovery and Protein Engineering, MedImmune, Gaithersburg, MD, USA
| | - Herren Wu
- Antibody Discovery and Protein Engineering, MedImmune, Gaithersburg, MD, USA
| | | | - Marcello Marelli
- Antibody Discovery and Protein Engineering, MedImmune, Gaithersburg, MD, USA
| | - Yariv Mazor
- Antibody Discovery and Protein Engineering, MedImmune, Gaithersburg, MD, USA
| |
Collapse
|
8
|
Taylor DK, Mittereder N, Kuta E, Delaney T, Burwell T, Dacosta K, Zhao W, Cheng LI, Brown C, Boutrin A, Guo X, White WI, Zhu J, Dong H, Bowen MA, Lin J, Gao C, Yu L, Ramaswamy M, Gaudreau MC, Woods R, Herbst R, Carlesso G. T follicular helper–like cells contribute to skin fibrosis. Sci Transl Med 2018. [DOI: 10.1126/scitranslmed.aaf5307] [Citation(s) in RCA: 65] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|
9
|
Roy G, Martin T, Barnes A, Wang J, Jimenez RB, Rice M, Li L, Feng H, Zhang S, Chaerkady R, Wu H, Marelli M, Hatton D, Zhu J, Bowen MA. A novel bicistronic gene design couples stable cell line selection with a fucose switch in a designer CHO host to produce native and afucosylated glycoform antibodies. MAbs 2018; 10:416-430. [PMID: 29400603 PMCID: PMC5916560 DOI: 10.1080/19420862.2018.1433975] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
The conserved glycosylation site Asn297 of a monoclonal antibody (mAb) can be decorated with a variety of sugars that can alter mAb pharmacokinetics and recruitment of effector proteins. Antibodies lacking the core fucose at Asn297 (afucosylated mAbs) show enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) and increased efficacy. Here, we describe the development of a robust platform for the manufacture of afucosylated therapeutic mAbs by engineering a Chinese hamster ovary (CHO) host cell line to co-express a mAb with GDP-6-deoxy-D-lyxo-4-hexulose reductase (RMD), a prokaryotic enzyme that deflects an intermediate in the de novo synthesis of fucose to a dead-end product, resulting in the production of afucosylated mAb (GlymaxX™ Technology, ProBioGen). Expression of the mAb and RMD genes was coordinated by co-transfection of separate mAb and RMD vectors or use of an internal ribosome entry site (IRES) element to link the translation of RMD with either the glutamine synthase selection marker or the mAb light chain. The GS-IRES-RMD vector format was more suitable for the rapid generation of high yielding cell lines, secreting afucosylated mAb with titers exceeding 6.0 g/L. These cell lines maintained production of afucosylated mAb over 60 generations, ensuring their suitability for use in large-scale manufacturing. The afucosylated mAbs purified from these RMD-engineered cell lines showed increased binding in a CD16 cellular assay, demonstrating enhancement of ADCC compared to fucosylated control mAb. Furthermore, the afucosylation in these mAbs could be controlled by simple addition of L-fucose in the culture medium, thereby allowing the use of a single cell line for production of the same mAb in fucosylated and afucosylated formats for multiple therapeutic indications.
Collapse
Affiliation(s)
- Gargi Roy
- a Antibody Discovery and Protein Engineering , MedImmune LLC , Gaithersburg , Maryland , United States of America
| | - Tom Martin
- a Antibody Discovery and Protein Engineering , MedImmune LLC , Gaithersburg , Maryland , United States of America
| | - Arnita Barnes
- a Antibody Discovery and Protein Engineering , MedImmune LLC , Gaithersburg , Maryland , United States of America
| | - Jihong Wang
- b Analytical Biochemistry, MedImmune LLC , Gaithersburg , Maryland , United States of America
| | - Rod Brian Jimenez
- b Analytical Biochemistry, MedImmune LLC , Gaithersburg , Maryland , United States of America
| | - Megan Rice
- a Antibody Discovery and Protein Engineering , MedImmune LLC , Gaithersburg , Maryland , United States of America
| | - Lina Li
- c Cell Culture and Fermentation Sciences, MedImmune LLC , Gaithersburg , Maryland , United States of America
| | - Hui Feng
- a Antibody Discovery and Protein Engineering , MedImmune LLC , Gaithersburg , Maryland , United States of America
| | - Shu Zhang
- a Antibody Discovery and Protein Engineering , MedImmune LLC , Gaithersburg , Maryland , United States of America
| | - Raghothama Chaerkady
- a Antibody Discovery and Protein Engineering , MedImmune LLC , Gaithersburg , Maryland , United States of America
| | - Herren Wu
- a Antibody Discovery and Protein Engineering , MedImmune LLC , Gaithersburg , Maryland , United States of America
| | - Marcello Marelli
- a Antibody Discovery and Protein Engineering , MedImmune LLC , Gaithersburg , Maryland , United States of America
| | - Diane Hatton
- d Cell Culture and Fermentation Sciences, Biopharmaceutical Development, MedImmune , Cambridge , United Kingdom
| | - Jie Zhu
- c Cell Culture and Fermentation Sciences, MedImmune LLC , Gaithersburg , Maryland , United States of America
| | - Michael A Bowen
- a Antibody Discovery and Protein Engineering , MedImmune LLC , Gaithersburg , Maryland , United States of America
| |
Collapse
|
10
|
Heffner KM, Hizal DB, Yerganian GS, Kumar A, Can Ö, O’Meally R, Cole R, Chaerkady R, Wu H, Bowen MA, Betenbaugh MJ. Lessons from the Hamster: Cricetulus griseus Tissue and CHO Cell Line Proteome Comparison. J Proteome Res 2017; 16:3672-3687. [DOI: 10.1021/acs.jproteome.7b00382] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
| | | | | | - Amit Kumar
- Johns Hopkins University, Baltimore, Maryland 21218, United States
| | - Özge Can
- Acibadem University, Medical Biochemistry, Istanbul, Maltepe, Turkey
| | - Robert O’Meally
- Johns Hopkins Medical Institute, Baltimore, Maryland 21205, United States
| | - Robert Cole
- Johns Hopkins Medical Institute, Baltimore, Maryland 21205, United States
| | | | - Herren Wu
- MedImmune, Gaithersburg, Maryland 20878, United States
| | | | | |
Collapse
|
11
|
Douthwaite J, Moisan J, Privezentzev C, Soskic B, Sabbah S, Cohen S, Collinson A, England E, Huntington C, Kemp B, Zhuang L, Hudak S, Rees DG, Goldberg D, Barton C, Chang L, Vainshtein I, Liang M, Iciek L, Ambery P, Peakman M, Vaughan TJ, Tree TIM, Sansom DM, Bowen MA, Minter RR, Jermutus L. Correction: A CD80-Biased CTLA4-Ig Fusion Protein with Superior In Vivo Efficacy by Simultaneous Engineering of Affinity, Selectivity, Stability, and FcRn Binding. J I 2017; 199:1943. [DOI: 10.4049/jimmunol.1790013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
12
|
D’Angelo G, Chaerkady R, Yu W, Hizal DB, Hess S, Zhao W, Lekstrom K, Guo X, White WI, Roskos L, Bowen MA, Yang H. Statistical Models for the Analysis of Isobaric Tags Multiplexed Quantitative Proteomics. J Proteome Res 2017; 16:3124-3136. [DOI: 10.1021/acs.jproteome.6b01050] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Gina D’Angelo
- Statistical
Sciences, ‡Antibody Discovery and Protein Engineering, Protein Sciences, §Research Bioinformatics, ∥Clinical Biomarkers
and Computational Biology, and ⊥Clinical Pharmacology, Pharmacometrics, and
DMPK, MedImmune, Gaithersburg, Maryland 20878, United States
| | - Raghothama Chaerkady
- Statistical
Sciences, ‡Antibody Discovery and Protein Engineering, Protein Sciences, §Research Bioinformatics, ∥Clinical Biomarkers
and Computational Biology, and ⊥Clinical Pharmacology, Pharmacometrics, and
DMPK, MedImmune, Gaithersburg, Maryland 20878, United States
| | - Wen Yu
- Statistical
Sciences, ‡Antibody Discovery and Protein Engineering, Protein Sciences, §Research Bioinformatics, ∥Clinical Biomarkers
and Computational Biology, and ⊥Clinical Pharmacology, Pharmacometrics, and
DMPK, MedImmune, Gaithersburg, Maryland 20878, United States
| | - Deniz Baycin Hizal
- Statistical
Sciences, ‡Antibody Discovery and Protein Engineering, Protein Sciences, §Research Bioinformatics, ∥Clinical Biomarkers
and Computational Biology, and ⊥Clinical Pharmacology, Pharmacometrics, and
DMPK, MedImmune, Gaithersburg, Maryland 20878, United States
| | - Sonja Hess
- Statistical
Sciences, ‡Antibody Discovery and Protein Engineering, Protein Sciences, §Research Bioinformatics, ∥Clinical Biomarkers
and Computational Biology, and ⊥Clinical Pharmacology, Pharmacometrics, and
DMPK, MedImmune, Gaithersburg, Maryland 20878, United States
| | - Wei Zhao
- Statistical
Sciences, ‡Antibody Discovery and Protein Engineering, Protein Sciences, §Research Bioinformatics, ∥Clinical Biomarkers
and Computational Biology, and ⊥Clinical Pharmacology, Pharmacometrics, and
DMPK, MedImmune, Gaithersburg, Maryland 20878, United States
| | - Kristen Lekstrom
- Statistical
Sciences, ‡Antibody Discovery and Protein Engineering, Protein Sciences, §Research Bioinformatics, ∥Clinical Biomarkers
and Computational Biology, and ⊥Clinical Pharmacology, Pharmacometrics, and
DMPK, MedImmune, Gaithersburg, Maryland 20878, United States
| | - Xiang Guo
- Statistical
Sciences, ‡Antibody Discovery and Protein Engineering, Protein Sciences, §Research Bioinformatics, ∥Clinical Biomarkers
and Computational Biology, and ⊥Clinical Pharmacology, Pharmacometrics, and
DMPK, MedImmune, Gaithersburg, Maryland 20878, United States
| | - Wendy I. White
- Statistical
Sciences, ‡Antibody Discovery and Protein Engineering, Protein Sciences, §Research Bioinformatics, ∥Clinical Biomarkers
and Computational Biology, and ⊥Clinical Pharmacology, Pharmacometrics, and
DMPK, MedImmune, Gaithersburg, Maryland 20878, United States
| | - Lorin Roskos
- Statistical
Sciences, ‡Antibody Discovery and Protein Engineering, Protein Sciences, §Research Bioinformatics, ∥Clinical Biomarkers
and Computational Biology, and ⊥Clinical Pharmacology, Pharmacometrics, and
DMPK, MedImmune, Gaithersburg, Maryland 20878, United States
| | - Michael A. Bowen
- Statistical
Sciences, ‡Antibody Discovery and Protein Engineering, Protein Sciences, §Research Bioinformatics, ∥Clinical Biomarkers
and Computational Biology, and ⊥Clinical Pharmacology, Pharmacometrics, and
DMPK, MedImmune, Gaithersburg, Maryland 20878, United States
| | - Harry Yang
- Statistical
Sciences, ‡Antibody Discovery and Protein Engineering, Protein Sciences, §Research Bioinformatics, ∥Clinical Biomarkers
and Computational Biology, and ⊥Clinical Pharmacology, Pharmacometrics, and
DMPK, MedImmune, Gaithersburg, Maryland 20878, United States
| |
Collapse
|
13
|
Zhang Y, Baycin-Hizal D, Kumar A, Priola J, Bahri M, Heffner KM, Wang M, Han X, Bowen MA, Betenbaugh MJ. High-Throughput Lipidomic and Transcriptomic Analysis To Compare SP2/0, CHO, and HEK-293 Mammalian Cell Lines. Anal Chem 2017; 89:1477-1485. [DOI: 10.1021/acs.analchem.6b02984] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Yue Zhang
- Department
of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, Maryland 21218, United States
| | - Deniz Baycin-Hizal
- Antibody
Discovery and Protein Engineering, MedImmune LLC, Gaithersburg, Maryland 20878, United States
| | - Amit Kumar
- Department
of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, Maryland 21218, United States
| | - Joseph Priola
- Department
of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, Maryland 21218, United States
| | - Michelle Bahri
- Department
of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, Maryland 21218, United States
| | - Kelley M. Heffner
- Department
of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, Maryland 21218, United States
| | - Miao Wang
- Center
for Metabolic Origins of Disease, Sanford Burnham Prebys Medical Discovery Institute, Orlando, Florida 32827, United States
| | - Xianlin Han
- Center
for Metabolic Origins of Disease, Sanford Burnham Prebys Medical Discovery Institute, Orlando, Florida 32827, United States
| | - Michael A. Bowen
- Antibody
Discovery and Protein Engineering, MedImmune LLC, Gaithersburg, Maryland 20878, United States
| | - Michael J. Betenbaugh
- Department
of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, Maryland 21218, United States
| |
Collapse
|
14
|
Dimasi N, Fleming R, Sachsenmeier KF, Bezabeh B, Hay C, Wu J, Sult E, Rajan S, Zhuang L, Cariuk P, Buchanan A, Bowen MA, Wu H, Gao C. Guiding bispecific monovalent antibody formation through proteolysis of IgG1 single-chain. MAbs 2017; 9:438-454. [PMID: 28055299 DOI: 10.1080/19420862.2016.1277301] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
We developed an IgG1 domain-tethering approach to guide the correct assembly of 2 light and 2 heavy chains, derived from 2 different antibodies, to form bispecific monovalent antibodies in IgG1 format. We show here that assembling 2 different light and heavy chains by sequentially connecting them with protease-cleavable polypeptide linkers results in the generation of monovalent bispecific antibodies that have IgG1 sequence, structure and functional properties. This approach was used to generate a bispecific monovalent antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor that: 1) can be produced and purified using standard IgG1 techniques; 2) exhibits stability and structural features comparable to IgG1; 3) binds both targets simultaneously; and 4) has potent anti-tumor activity. Our strategy provides new engineering opportunities for bispecific antibody applications, and, most importantly, overcomes some of the limitations (e.g., half-antibody and homodimer formation, light chains mispairing, multi-step purification), inherent with some of the previously described IgG1-based bispecific monovalent antibodies.
Collapse
Affiliation(s)
- Nazzareno Dimasi
- a Antibody Discovery and Protein Engineering, MedImmune , Gaithersburg , MD , USA
| | - Ryan Fleming
- a Antibody Discovery and Protein Engineering, MedImmune , Gaithersburg , MD , USA
| | | | - Binyam Bezabeh
- a Antibody Discovery and Protein Engineering, MedImmune , Gaithersburg , MD , USA
| | - Carl Hay
- c Oncology Research, MedImmune , Gaithersburg , MD , USA
| | - Jincheng Wu
- d Research Bioinformatics, MedImmune , Gaithersburg , MD , USA
| | - Erin Sult
- c Oncology Research, MedImmune , Gaithersburg , MD , USA
| | - Saravanan Rajan
- a Antibody Discovery and Protein Engineering, MedImmune , Gaithersburg , MD , USA
| | - Li Zhuang
- a Antibody Discovery and Protein Engineering, MedImmune , Gaithersburg , MD , USA
| | - Peter Cariuk
- e Antibody Discovery and Protein Engineering, MedImmune , Cambridge , UK
| | - Andrew Buchanan
- e Antibody Discovery and Protein Engineering, MedImmune , Cambridge , UK
| | - Michael A Bowen
- a Antibody Discovery and Protein Engineering, MedImmune , Gaithersburg , MD , USA
| | - Herren Wu
- a Antibody Discovery and Protein Engineering, MedImmune , Gaithersburg , MD , USA
| | - Changshou Gao
- a Antibody Discovery and Protein Engineering, MedImmune , Gaithersburg , MD , USA
| |
Collapse
|
15
|
Douthwaite J, Moisan J, Privezentzev C, Soskic B, Sabbah S, Cohen S, Collinson A, England E, Huntington C, Kemp B, Zhuang L, Hudak S, Rees DG, Goldberg D, Barton C, Chang L, Vainshtein I, Liang M, Iciek L, Ambery P, Peakman M, Vaughan TJ, Tree TIM, Sansom DM, Bowen MA, Minter RR, Jermutus L. A CD80-Biased CTLA4-Ig Fusion Protein with Superior In Vivo Efficacy by Simultaneous Engineering of Affinity, Selectivity, Stability, and FcRn Binding. J Immunol 2017; 198:528-537. [PMID: 27881707 DOI: 10.4049/jimmunol.1600682] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/18/2016] [Accepted: 10/13/2016] [Indexed: 12/16/2022]
Abstract
Affinity- and stability-engineered variants of CTLA4-Ig fusion molecules with enhanced pharmacokinetic profiles could yield improved therapies with the potential of higher efficacy and greater convenience to patients. In this study, to our knowledge, we have, for the first time, used in vitro evolution to simultaneously optimize CTLA4 affinity and stability. We selected for improved binding to both ligands, CD80 and CD86, and screened as dimeric Fc fusions directly in functional assays to identify variants with stronger suppression of in vitro T cell activation. The majority of CTLA4 molecules showing the largest potency gains in primary in vitro and ex vivo human cell assays, using PBMCs from type 1 diabetes patients, had significant improvements in CD80, but only modest gains in CD86 binding. We furthermore observed different potency rankings between our lead molecule MEDI5265, abatacept, and belatacept, depending on which type of APC was used, with MEDI5265 consistently being the most potent. We then created fusions of both stability- and potency-optimized CTLA4 moieties with human Fc variants conferring extended plasma t1/2 In a cynomolgus model of T cell-dependent Ab response, the CTLA4-Ig variant MEDI5265 could be formulated at >100 mg/ml for s.c. administration and showed superior efficacy and significantly prolonged serum t1/2 The combination of higher stability and potency with prolonged pharmacokinetics could be compatible with very infrequent, s.c. dosing while maintaining a similar level of immune suppression to more frequently and i.v. administered licensed therapies.
Collapse
Affiliation(s)
| | | | | | - Blagoje Soskic
- Royal Free Campus, Institute of Immunity and Transplantation, University College London, London NW3 2PF, United Kingdom
| | - Shereen Sabbah
- Department of Immunobiology, King's College London, London SE1 9RT, United Kingdom
- Faculty of Life Sciences and Medicine, King's College London, London SE1 9RT, United Kingdom
- National Institutes of Health Research Biomedical Research Centre at Guy's and St. Thomas' National Health Service Foundation Trust, London SE1 9RT, United Kingdom; and
| | | | | | | | | | - Ben Kemp
- MedImmune, Cambridge CB21 6GH, United Kingdom
| | | | | | | | | | | | | | | | | | | | | | - Mark Peakman
- Department of Immunobiology, King's College London, London SE1 9RT, United Kingdom
- Faculty of Life Sciences and Medicine, King's College London, London SE1 9RT, United Kingdom
- National Institutes of Health Research Biomedical Research Centre at Guy's and St. Thomas' National Health Service Foundation Trust, London SE1 9RT, United Kingdom; and
| | | | - Tim I M Tree
- Department of Immunobiology, King's College London, London SE1 9RT, United Kingdom
- Faculty of Life Sciences and Medicine, King's College London, London SE1 9RT, United Kingdom
- National Institutes of Health Research Biomedical Research Centre at Guy's and St. Thomas' National Health Service Foundation Trust, London SE1 9RT, United Kingdom; and
| | - David M Sansom
- Royal Free Campus, Institute of Immunity and Transplantation, University College London, London NW3 2PF, United Kingdom
| | | | | | | |
Collapse
|
16
|
Rickert KW, Grinberg L, Woods RM, Wilson S, Bowen MA, Baca M. Combining phage display with de novo protein sequencing for reverse engineering of monoclonal antibodies. MAbs 2016; 8:501-12. [PMID: 26852694 DOI: 10.1080/19420862.2016.1145865] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
Abstract
The enormous diversity created by gene recombination and somatic hypermutation makes de novo protein sequencing of monoclonal antibodies a uniquely challenging problem. Modern mass spectrometry-based sequencing will rarely, if ever, provide a single unambiguous sequence for the variable domains. A more likely outcome is computation of an ensemble of highly similar sequences that can satisfy the experimental data. This outcome can result in the need for empirical testing of many candidate sequences, sometimes iteratively, to identity one which can replicate the activity of the parental antibody. Here we describe an improved approach to antibody protein sequencing by using phage display technology to generate a combinatorial library of sequences that satisfy the mass spectrometry data, and selecting for functional candidates that bind antigen. This approach was used to reverse engineer 2 commercially-obtained monoclonal antibodies against murine CD137. Proteomic data enabled us to assign the majority of the variable domain sequences, with the exception of 3-5% of the sequence located within or adjacent to complementarity-determining regions. To efficiently resolve the sequence in these regions, small phage-displayed libraries were generated and subjected to antigen binding selection. Following enrichment of antigen-binding clones, 2 clones were selected for each antibody and recombinantly expressed as antigen-binding fragments (Fabs). In both cases, the reverse-engineered Fabs exhibited identical antigen binding affinity, within error, as Fabs produced from the commercial IgGs. This combination of proteomic and protein engineering techniques provides a useful approach to simplifying the technically challenging process of reverse engineering monoclonal antibodies from protein material.
Collapse
Affiliation(s)
- Keith W Rickert
- a Department of Antibody Discovery and Protein Engineering , MedImmune, LLC , Gaithersburg , MD , USA
| | - Luba Grinberg
- a Department of Antibody Discovery and Protein Engineering , MedImmune, LLC , Gaithersburg , MD , USA
| | - Robert M Woods
- a Department of Antibody Discovery and Protein Engineering , MedImmune, LLC , Gaithersburg , MD , USA
| | - Susan Wilson
- a Department of Antibody Discovery and Protein Engineering , MedImmune, LLC , Gaithersburg , MD , USA
| | - Michael A Bowen
- a Department of Antibody Discovery and Protein Engineering , MedImmune, LLC , Gaithersburg , MD , USA
| | - Manuel Baca
- a Department of Antibody Discovery and Protein Engineering , MedImmune, LLC , Gaithersburg , MD , USA
| |
Collapse
|
17
|
Tsui P, Higazi DR, Wu Y, Dunmore R, Solier E, Kasali T, Bond NJ, Huntington C, Carruthers A, Hood J, Borrok MJ, Barnes A, Rickert K, Phipps S, Shirinian L, Zhu J, Bowen MA, Dall'Acqua W, Murray LA. The TGF-β inhibitory activity of antibody 37E1B5 depends on its H-CDR2 glycan. MAbs 2016; 9:104-113. [PMID: 27834568 DOI: 10.1080/19420862.2016.1255390] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
Abstract
Excessive transforming growth factor (TGF)-β is associated with pro-fibrotic responses in lung disease, yet it also plays essential roles in tissue homeostasis and autoimmunity. Therefore, selective inhibition of excessive and aberrant integrin-mediated TGF-β activation via targeting the α-v family of integrins is being pursued as a therapeutic strategy for chronic lung diseases, to mitigate any potential safety concerns with global TGF-β inhibition. In this work, we reveal a novel mechanism of inhibiting TGF-β activation utilized by an αvβ8 targeting antibody, 37E1B5. This antibody blocks TGF-β activation while not inhibiting cell adhesion. We show that an N-linked complex-type Fab glycan in H-CDR2 of 37E1B5 is directly involved in the inhibition of latent TGF-β activation. Removal of the Fab N-glycosylation site by single amino acid substitution, or removal of N-linked glycans by enzymatic digestion, drastically reduced the antibody's ability to inhibit latency-associated peptide (LAP) and αvβ8 association, and TGF-β activation in an αvβ8-mediated TGF-β signaling reporter assay. Our results indicate a non-competitive, allosteric inhibition of 37E1B5 on αvβ8-mediated TGF-β activation. This unique, H-CDR2 glycan-mediated mechanism may account for the potent but tolerable TGF-b activation inhibition and lack of an effect on cellular adhesion by the antibody.
Collapse
Affiliation(s)
- Ping Tsui
- a Antibody Discovery and Protein Engineering, Medimmune LLC , Gaithersburg , MD , USA
| | - Daniel R Higazi
- b Biopharmaceutical Development, MedImmune Ltd , Cambridge , UK
| | - Yanli Wu
- a Antibody Discovery and Protein Engineering, Medimmune LLC , Gaithersburg , MD , USA
| | - Rebecca Dunmore
- c Respiratory, Inflammation and Autoimmunity, MedImmune Ltd , Cambridge , UK
| | - Emilie Solier
- b Biopharmaceutical Development, MedImmune Ltd , Cambridge , UK
| | - Toyin Kasali
- b Biopharmaceutical Development, MedImmune Ltd , Cambridge , UK
| | - Nicholas J Bond
- b Biopharmaceutical Development, MedImmune Ltd , Cambridge , UK
| | | | - Alan Carruthers
- c Respiratory, Inflammation and Autoimmunity, MedImmune Ltd , Cambridge , UK
| | - John Hood
- e Translational Sciences, Medimmune Ltd ., Cambridge , UK
| | - M Jack Borrok
- a Antibody Discovery and Protein Engineering, Medimmune LLC , Gaithersburg , MD , USA
| | - Arnita Barnes
- a Antibody Discovery and Protein Engineering, Medimmune LLC , Gaithersburg , MD , USA
| | - Keith Rickert
- a Antibody Discovery and Protein Engineering, Medimmune LLC , Gaithersburg , MD , USA
| | - Sandrina Phipps
- a Antibody Discovery and Protein Engineering, Medimmune LLC , Gaithersburg , MD , USA
| | - Lena Shirinian
- a Antibody Discovery and Protein Engineering, Medimmune LLC , Gaithersburg , MD , USA
| | - Jie Zhu
- a Antibody Discovery and Protein Engineering, Medimmune LLC , Gaithersburg , MD , USA
| | - Michael A Bowen
- a Antibody Discovery and Protein Engineering, Medimmune LLC , Gaithersburg , MD , USA
| | - William Dall'Acqua
- a Antibody Discovery and Protein Engineering, Medimmune LLC , Gaithersburg , MD , USA
| | - Lynne A Murray
- c Respiratory, Inflammation and Autoimmunity, MedImmune Ltd , Cambridge , UK
| |
Collapse
|
18
|
Zhang Z, Yang X, Mirokhin YA, Tchekhovskoi DV, Ji W, Markey SP, Roth J, Neta P, Hizal DB, Bowen MA, Stein SE. Interconversion of Peptide Mass Spectral Libraries Derivatized with iTRAQ or TMT Labels. J Proteome Res 2016; 15:3180-7. [DOI: 10.1021/acs.jproteome.6b00406] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Zheng Zhang
- Mass
Spectrometry Data Center, National Institute of Standards and Technology, 100 Bureau Drive, Gaithersburg, Maryland 20899, United States
| | - Xiaoyu Yang
- Mass
Spectrometry Data Center, National Institute of Standards and Technology, 100 Bureau Drive, Gaithersburg, Maryland 20899, United States
| | - Yuri A. Mirokhin
- Mass
Spectrometry Data Center, National Institute of Standards and Technology, 100 Bureau Drive, Gaithersburg, Maryland 20899, United States
| | - Dmitrii V. Tchekhovskoi
- Mass
Spectrometry Data Center, National Institute of Standards and Technology, 100 Bureau Drive, Gaithersburg, Maryland 20899, United States
| | - Weihua Ji
- Mass
Spectrometry Data Center, National Institute of Standards and Technology, 100 Bureau Drive, Gaithersburg, Maryland 20899, United States
| | - Sanford P. Markey
- Mass
Spectrometry Data Center, National Institute of Standards and Technology, 100 Bureau Drive, Gaithersburg, Maryland 20899, United States
| | - Jeri Roth
- Mass
Spectrometry Data Center, National Institute of Standards and Technology, 100 Bureau Drive, Gaithersburg, Maryland 20899, United States
| | - Pedatsur Neta
- Mass
Spectrometry Data Center, National Institute of Standards and Technology, 100 Bureau Drive, Gaithersburg, Maryland 20899, United States
| | - Deniz Baycin Hizal
- Antibody
Discovery and Protein Engineering Department, MedImmune LLC, One MedImmune
Way, Gaithersburg, Maryland 20878, United States
| | - Michael A. Bowen
- Antibody
Discovery and Protein Engineering Department, MedImmune LLC, One MedImmune
Way, Gaithersburg, Maryland 20878, United States
| | - Stephen E. Stein
- Mass
Spectrometry Data Center, National Institute of Standards and Technology, 100 Bureau Drive, Gaithersburg, Maryland 20899, United States
| |
Collapse
|
19
|
Kumar A, Baycin-Hizal D, Zhang Y, Bowen MA, Betenbaugh MJ. Cellular traffic cops: the interplay between lipids and proteins regulates vesicular formation, trafficking, and signaling in mammalian cells. Curr Opin Biotechnol 2015; 36:215-21. [PMID: 26540512 DOI: 10.1016/j.copbio.2015.09.006] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2015] [Revised: 08/18/2015] [Accepted: 09/17/2015] [Indexed: 11/30/2022]
Abstract
Protein secretion and vesicular trafficking in mammalian cells rely on several key lipids including sphingolipids, phospholipids, and neutral lipids crucial to protein processing and other intracellular events. Proteins interact with these lipids to alter the shape of lipid bilayer, thereby playing a pivotal role in cellular sorting. Although some efforts have elucidated the role of these components, extensive studies are needed to further decipher the protein-lipid interactions along with the effect of membrane curvature and rafts in sorting of proteins. The regulatory role of proteins in subcellular localization and metabolism of lipids also needs to be described. Recent studies on the role of lipid-protein interactions in modulating membrane shape, signal transduction, and vesicular trafficking are presented in this review.
Collapse
Affiliation(s)
- Amit Kumar
- Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD 21218, USA
| | - Deniz Baycin-Hizal
- Antibody Discovery and Protein Engineering, MedImmune, Gaithersburg, MD 20878, USA
| | - Yue Zhang
- Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD 21218, USA
| | - Michael A Bowen
- Antibody Discovery and Protein Engineering, MedImmune, Gaithersburg, MD 20878, USA
| | - Michael J Betenbaugh
- Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD 21218, USA.
| |
Collapse
|
20
|
Nour SG, Powell TE, Eberhardt J, Bowen MA, Pennington G, Meltzer CC. Interventional Magnetic Resonance Imaging Clinic. Magn Reson Imaging Clin N Am 2015; 23:681-8. [DOI: 10.1016/j.mric.2015.07.001] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
21
|
Oganesyan V, Mazor Y, Yang C, Cook KE, Woods RM, Ferguson A, Bowen MA, Martin T, Zhu J, Wu H, Dall’Acqua WF. Structural insights into the interaction of human IgG1 with FcγRI: no direct role of glycans in binding. Acta Crystallogr D Biol Crystallogr 2015; 71:2354-61. [PMID: 26527150 PMCID: PMC4631484 DOI: 10.1107/s1399004715018015] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/20/2015] [Accepted: 09/25/2015] [Indexed: 11/10/2022]
Abstract
The three-dimensional structure of a human IgG1 Fc fragment bound to wild-type human FcγRI is reported. The structure of the corresponding complex was solved at a resolution of 2.4 Å using molecular replacement; this is the highest resolution achieved for an unmutated FcγRI molecule. This study highlights the critical structural and functional role played by the second extracellular subdomain of FcγRI. It also explains the long-known major energetic contribution of the Fc `LLGG' motif at positions 234-237, and particularly of Leu235, via a `lock-and-key' mechanism. Finally, a previously held belief is corrected and a differing view is offered on the recently proposed direct role of Fc carbohydrates in the corresponding interaction. Structural evidence is provided that such glycan-related effects are strictly indirect.
Collapse
Affiliation(s)
- Vaheh Oganesyan
- Department of Antibody Discovery and Protein Engineering, MedImmune LLC, 1 MedImmune Way, Gaithersburg, MD 20878, USA
| | - Yariv Mazor
- Department of Antibody Discovery and Protein Engineering, MedImmune LLC, 1 MedImmune Way, Gaithersburg, MD 20878, USA
| | - Chunning Yang
- Department of Antibody Discovery and Protein Engineering, MedImmune LLC, 1 MedImmune Way, Gaithersburg, MD 20878, USA
| | - Kimberly E. Cook
- Department of Antibody Discovery and Protein Engineering, MedImmune LLC, 1 MedImmune Way, Gaithersburg, MD 20878, USA
| | - Robert M. Woods
- Department of Antibody Discovery and Protein Engineering, MedImmune LLC, 1 MedImmune Way, Gaithersburg, MD 20878, USA
| | - Andrew Ferguson
- Discovery Sciences, Structure and Biophysics, AstraZeneca Pharmaceuticals, 35 Gatehouse Drive, Mailstop E3, Waltham, MA 02451, USA
| | - Michael A. Bowen
- Department of Antibody Discovery and Protein Engineering, MedImmune LLC, 1 MedImmune Way, Gaithersburg, MD 20878, USA
| | - Tom Martin
- Department of Antibody Discovery and Protein Engineering, MedImmune LLC, 1 MedImmune Way, Gaithersburg, MD 20878, USA
| | - Jie Zhu
- Biopharmaceutical Development, MedImmune LLC, 1 MedImmune Way, Gaithersburg, MD 20878, USA
| | - Herren Wu
- Department of Antibody Discovery and Protein Engineering, MedImmune LLC, 1 MedImmune Way, Gaithersburg, MD 20878, USA
| | - William F. Dall’Acqua
- Department of Antibody Discovery and Protein Engineering, MedImmune LLC, 1 MedImmune Way, Gaithersburg, MD 20878, USA
| |
Collapse
|
22
|
Kumar A, Baycin-Hizal D, Wolozny D, Pedersen LE, Lewis NE, Heffner K, Chaerkady R, Cole RN, Shiloach J, Zhang H, Bowen MA, Betenbaugh MJ. Elucidation of the CHO Super-Ome (CHO-SO) by Proteoinformatics. J Proteome Res 2015; 14:4687-703. [PMID: 26418914 DOI: 10.1021/acs.jproteome.5b00588] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Chinese hamster ovary (CHO) cells are the preferred host cell line for manufacturing a variety of complex biotherapeutic drugs including monoclonal antibodies. We performed a proteomics and bioinformatics analysis on the spent medium from adherent CHO cells. Supernatant from CHO-K1 culture was collected and subjected to in-solution digestion followed by LC/LC-MS/MS analysis, which allowed the identification of 3281 different host cell proteins (HCPs). To functionally categorize them, we applied multiple bioinformatics tools to the proteins identified in our study including SignalP, TargetP, SecretomeP, TMHMM, WoLF PSORT, and Phobius. This analysis provided information on the presence of signal peptides, transmembrane domains, and cellular localization and showed that both secreted and intracellular proteins were constituents of the supernatant. Identified proteins were shown to be localized to the secretory pathway including ones playing roles in cell growth, proliferation, and folding as well as those involved in protein degradation and removal. After combining proteins predicted to be secreted or having a signal peptide, we identified 1015 proteins, which we termed as CHO supernatant-ome (CHO-SO), or superome. As a part of this effort, we created a publically accessible web-based tool called GO-CHO to functionally categorize proteins found in CHO-SO and identify enriched molecular functions, biological processes, and cellular components. We also used a tool to evaluate the immunogenicity potential of high-abundance HCPs. Among enriched functions were catalytic activity and structural constituents of the cytoskeleton. Various transport related biological processes, such as vesicle mediated transport, were found to be highly enriched. Extracellular space and vesicular exosome associated proteins were found to be the most enriched cellular components. The superome also contained proteins secreted from both classical and nonclassical secretory pathways. The work and database described in our study will enable the CHO community to rapidly identify high-abundance HCPs in their cultures and therefore help assess process and purification methods used in the production of biologic drugs.
Collapse
Affiliation(s)
- Amit Kumar
- Department of Chemical and Biomolecular Engineering, Johns Hopkins University , Baltimore, Maryland 21218, United States.,Biotechnology Core Laboratory, National Institute of Diabetes and Digestive and Kidney Diseases , National Institute of Health, Building 14A, Bethesda, Maryland 20892, United States
| | - Deniz Baycin-Hizal
- Antibody Discovery and Protein Engineering, MedImmune LLC , 1 MedImmune Way, Gaithersburg, Maryland 20878, United States
| | - Daniel Wolozny
- Department of Chemical and Biomolecular Engineering, Johns Hopkins University , Baltimore, Maryland 21218, United States
| | - Lasse Ebdrup Pedersen
- The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark , DK-2970 Hørsholm, Denmark
| | - Nathan E Lewis
- Department of Biology, Brigham Young University , Provo, Utah 84602, United States.,Department of Pediatrics, University of California , San Diego, California 92093, United States
| | - Kelley Heffner
- Department of Chemical and Biomolecular Engineering, Johns Hopkins University , Baltimore, Maryland 21218, United States
| | - Raghothama Chaerkady
- Institute of Basic Biomedical Sciences, Mass Spectrometry and Proteomics Facility, Johns Hopkins University School of Medicine , 733 North Broadway Street, Baltimore, Maryland 21205, United States
| | - Robert N Cole
- Institute of Basic Biomedical Sciences, Mass Spectrometry and Proteomics Facility, Johns Hopkins University School of Medicine , 733 North Broadway Street, Baltimore, Maryland 21205, United States
| | - Joseph Shiloach
- Biotechnology Core Laboratory, National Institute of Diabetes and Digestive and Kidney Diseases , National Institute of Health, Building 14A, Bethesda, Maryland 20892, United States
| | - Hui Zhang
- Department of Pathology, Johns Hopkins School of Medicine , 400 North Broadway Street, Baltimore, Maryland 21287, United States
| | - Michael A Bowen
- Antibody Discovery and Protein Engineering, MedImmune LLC , 1 MedImmune Way, Gaithersburg, Maryland 20878, United States
| | - Michael J Betenbaugh
- Department of Chemical and Biomolecular Engineering, Johns Hopkins University , Baltimore, Maryland 21218, United States
| |
Collapse
|
23
|
VanBrunt MP, Shanebeck K, Caldwell Z, Johnson J, Thompson P, Martin T, Dong H, Li G, Xu H, D’Hooge F, Masterson L, Bariola P, Tiberghien A, Ezeadi E, Williams DG, Hartley JA, Howard PW, Grabstein KH, Bowen MA, Marelli M. Genetically Encoded Azide Containing Amino Acid in Mammalian Cells Enables Site-Specific Antibody–Drug Conjugates Using Click Cycloaddition Chemistry. Bioconjug Chem 2015; 26:2249-60. [DOI: 10.1021/acs.bioconjchem.5b00359] [Citation(s) in RCA: 84] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Michael P. VanBrunt
- Allozyne, Inc., 1600 Fairview Avenue
East, Seattle, Washington 98102, United States
| | - Kurt Shanebeck
- Allozyne, Inc., 1600 Fairview Avenue
East, Seattle, Washington 98102, United States
| | - Zachary Caldwell
- Allozyne, Inc., 1600 Fairview Avenue
East, Seattle, Washington 98102, United States
| | - Jeffrey Johnson
- Allozyne, Inc., 1600 Fairview Avenue
East, Seattle, Washington 98102, United States
| | - Pamela Thompson
- MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878, United States
| | - Thomas Martin
- MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878, United States
| | - Huifang Dong
- MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878, United States
| | - Gary Li
- Allozyne, Inc., 1600 Fairview Avenue
East, Seattle, Washington 98102, United States
| | - Hengyu Xu
- Allozyne, Inc., 1600 Fairview Avenue
East, Seattle, Washington 98102, United States
| | - Francois D’Hooge
- Spirogen MedImmune, The QMB Innovation Centre, 42 New Road, London E1
2AX, United Kingdom
| | - Luke Masterson
- Spirogen MedImmune, The QMB Innovation Centre, 42 New Road, London E1
2AX, United Kingdom
| | - Pauline Bariola
- Allozyne, Inc., 1600 Fairview Avenue
East, Seattle, Washington 98102, United States
| | - Arnaud Tiberghien
- Spirogen MedImmune, The QMB Innovation Centre, 42 New Road, London E1
2AX, United Kingdom
| | - Ebele Ezeadi
- Spirogen MedImmune, The QMB Innovation Centre, 42 New Road, London E1
2AX, United Kingdom
| | - David G. Williams
- Spirogen MedImmune, The QMB Innovation Centre, 42 New Road, London E1
2AX, United Kingdom
| | - John A. Hartley
- Spirogen MedImmune, The QMB Innovation Centre, 42 New Road, London E1
2AX, United Kingdom
- UCL Cancer Institute, 72
Huntley Street, London WC1E 6BT, United Kingdom
| | - Philip W. Howard
- Spirogen MedImmune, The QMB Innovation Centre, 42 New Road, London E1
2AX, United Kingdom
| | - Kenneth H. Grabstein
- Allozyne, Inc., 1600 Fairview Avenue
East, Seattle, Washington 98102, United States
| | - Michael A. Bowen
- MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878, United States
| | - Marcello Marelli
- Allozyne, Inc., 1600 Fairview Avenue
East, Seattle, Washington 98102, United States
- MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878, United States
| |
Collapse
|
24
|
Hawkins CM, Bowen MA, Gilliland CA, Walls DG, Duszak R. The Impact of Nonphysician Providers on Diagnostic and Interventional Radiology Practices: Operational and Educational Implications. J Am Coll Radiol 2015; 12:898-904. [DOI: 10.1016/j.jacr.2015.03.034] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2015] [Accepted: 03/23/2015] [Indexed: 01/05/2023]
|
25
|
Hawkins CM, Bowen MA, Gilliland CA, Walls DG, Duszak R. The Impact of Nonphysician Providers on Diagnostic and Interventional Radiology Practices: Regulatory, Billing, and Compliance Perspectives. J Am Coll Radiol 2015; 12:776-81. [DOI: 10.1016/j.jacr.2015.03.036] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2015] [Accepted: 03/23/2015] [Indexed: 01/02/2023]
|
26
|
Wu Y, Li JJ, Kim HJ, Liu X, Liu W, Akhgar A, Bowen MA, Spitz S, Jiang XR, Roskos LK, White WI. A Neutralizing Antibody Assay Based on a Reporter of Antibody-Dependent Cell-Mediated Cytotoxicity. AAPS J 2015. [PMID: 26205082 DOI: 10.1208/s12248-015-9798-5] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
Benralizumab is a humanized anti-IL5 receptor α (IL5Rα) monoclonal antibody (mAb) with enhanced (afucosylation) antibody-dependent cell-mediated cytotoxicity (ADCC) function. An ADCC reporter cell-based neutralizing antibody (NAb) assay was developed and characterized to detect NAb against benralizumab in human serum to support the clinical development of benralizumab. The optimal ratio of target cells to effector cells was 3:1. Neither parental benralizumab (fucosylated) nor benralizumab Fab resulted in ADCC activity, confirming the requirement for ADCC activity in the NAb assay. The serum tolerance of the cells was determined to be 2.5%. The cut point derived from normal and asthma serum samples was comparable. The effective range of benralizumab was determined, and 35 ng/mL [80% maximal effective concentration (EC80)] was chosen as the standard concentration to run in the assessment of NAb. An affinity purified goat anti-benralizumab polyclonal idiotype antibody preparation was shown to have NAb since it inhibited ADCC activity in a dose-dependent fashion. The low endogenous concentrations of IL5 and soluble IL5 receptor (sIL5R) did not demonstrate to interfere with the assay. The estimated assay sensitivities at the cut point were 1.02 and 1.10 μg/mL as determined by the surrogate neutralizing goat polyclonal and mouse monoclonal anti-drug antibody (ADA) controls, respectively. The assay can detect NAb (at 2.5 μg/mL) in the presence of 0.78 μg/mL benralizumab. The assay was not susceptible to non-specific matrix effects. This study provides an approach and feasibility of developing an ADCC cell-based NAb assay to support biopharmaceuticals with an ADCC function.
Collapse
Affiliation(s)
- Yuling Wu
- Clinical Pharmacology and DMPK, MedImmune LLC, One MedImmune Way, Gaithersburg, Maryland, 20878, USA.
| | - Jia J Li
- Clinical Pharmacology and DMPK, MedImmune LLC, One MedImmune Way, Gaithersburg, Maryland, 20878, USA
| | - Hyun Jun Kim
- Analytical Biotechnology Development, MedImmune LLC, One MedImmune Way, Gaithersburg, Maryland, 20878, USA
| | - Xu Liu
- Clinical Pharmacology and DMPK, MedImmune LLC, One MedImmune Way, Gaithersburg, Maryland, 20878, USA
| | - Weiyi Liu
- Clinical Pharmacology and DMPK, MedImmune LLC, One MedImmune Way, Gaithersburg, Maryland, 20878, USA
| | - Ahmad Akhgar
- Clinical Pharmacology and DMPK, MedImmune LLC, One MedImmune Way, Gaithersburg, Maryland, 20878, USA
| | - Michael A Bowen
- Antibody Development and Protein Engineering, MedImmune LLC, One MedImmune Way, Gaithersburg, Maryland, 20878, USA
| | - Susan Spitz
- Clinical Pharmacology and DMPK, MedImmune LLC, One MedImmune Way, Gaithersburg, Maryland, 20878, USA
| | - Xu-Rong Jiang
- Analytical Biotechnology Development, MedImmune LLC, One MedImmune Way, Gaithersburg, Maryland, 20878, USA
| | - Lorin K Roskos
- Clinical Pharmacology and DMPK, MedImmune LLC, One MedImmune Way, Gaithersburg, Maryland, 20878, USA
| | - Wendy I White
- Clinical Pharmacology and DMPK, MedImmune LLC, One MedImmune Way, Gaithersburg, Maryland, 20878, USA
| |
Collapse
|
27
|
Nyborg AC, Zacco A, Ettinger R, Jack Borrok M, Zhu J, Martin T, Woods R, Kiefer C, Bowen MA, Suzanne Cohen E, Herbst R, Wu H, Coats S. Development of an antibody that neutralizes soluble IgE and eliminates IgE expressing B cells. Cell Mol Immunol 2015; 13:391-400. [PMID: 25942513 PMCID: PMC4856805 DOI: 10.1038/cmi.2015.19] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2014] [Revised: 02/10/2015] [Accepted: 02/11/2015] [Indexed: 12/26/2022] Open
Abstract
Immunoglobulin E (IgE) plays a key role in allergic asthma and is a clinically validated target for monoclonal antibodies. Therapeutic anti-IgE antibodies block the interaction between IgE and the Fc epsilon (Fcε) receptor, which eliminates or minimizes the allergic phenotype but does not typically curtail the ongoing production of IgE by B cells. We generated high-affinity anti-IgE antibodies (MEDI4212) that have the potential to both neutralize soluble IgE and eliminate IgE-expressing B-cells through antibody-dependent cell-mediated cytotoxicity. MEDI4212 variants were generated that contain mutations in the Fc region of the antibody or alterations in fucosylation in order to enhance the antibody's affinity for FcγRIIIa. All MEDI4212 variants bound to human IgE with affinities comparable to the wild-type (WT) antibody. Each variant was shown to inhibit the interaction between IgE and FcεRI, which translated into potent inhibition of FcγRI-mediated function responses. Importantly, all variants bound similarly to IgE at the surface of membrane IgE expressing cells. However, MEDI4212 variants demonstrated enhanced affinity for FcγRIIIa including the polymorphic variants at position 158. The improvement in FcγRIIIa binding led to increased effector function in cell based assays using both engineered cell lines and class switched human IgE B cells. Through its superior suppression of IgE, we anticipate that effector function enhanced MEDI4212 may be able to neutralize high levels of soluble IgE and provide increased long-term benefit by eliminating the IgE expressing B cells before they differentiate and become IgE secreting plasma cells.
Collapse
Affiliation(s)
| | | | | | | | - Jie Zhu
- MedImmune LLC, Gaithersburg, MD, USA
| | | | - Rob Woods
- MedImmune LLC, Gaithersburg, MD, USA
| | | | | | - E Suzanne Cohen
- MedImmune Ltd, Milstein Building, Granta Park, Cambridge, UK
| | | | - Herren Wu
- MedImmune LLC, Gaithersburg, MD, USA
| | | |
Collapse
|
28
|
Duszak R, Walls DG, Wang JM, Hemingway J, Hughes DR, Small WC, Bowen MA. Expanding Roles of Nurse Practitioners and Physician Assistants As Providers of Nonvascular Invasive Radiology Procedures. J Am Coll Radiol 2015; 12:284-9. [DOI: 10.1016/j.jacr.2014.08.021] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2014] [Accepted: 08/26/2014] [Indexed: 11/16/2022]
|
29
|
Kumar A, Baycin-Hizal D, Shiloach J, Bowen MA, Betenbaugh MJ. Coupling enrichment methods with proteomics for understanding and treating disease. Proteomics Clin Appl 2015; 9:33-47. [PMID: 25523641 DOI: 10.1002/prca.201400097] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2014] [Revised: 11/12/2014] [Accepted: 12/15/2014] [Indexed: 12/17/2022]
Abstract
Owing to recent advances in proteomics analytical methods and bioinformatics capabilities there is a growing trend toward using these capabilities for the development of drugs to treat human disease, including target and drug evaluation, understanding mechanisms of drug action, and biomarker discovery. Currently, the genetic sequences of many major organisms are available, which have helped greatly in characterizing proteomes in model animal systems and humans. Through proteomics, global profiles of different disease states can be characterized (e.g. changes in types and relative levels as well as changes in PTMs such as glycosylation or phosphorylation). Although intracellular proteomics can provide a broad overview of physiology of cells and tissues, it has been difficult to quantify the low abundance proteins which can be important for understanding the diseased states and treatment progression. For this reason, there is increasing interest in coupling comparative proteomics methods with subcellular fractionation and enrichment techniques for membranes, nucleus, phosphoproteome, glycoproteome as well as low abundance serum proteins. In this review, we will provide examples of where the utilization of different proteomics-coupled enrichment techniques has aided target and biomarker discovery, understanding the drug targeting mechanism, and mAb discovery. Taken together, these improvements will help to provide a better understanding of the pathophysiology of various diseases including cancer, autoimmunity, inflammation, cardiovascular disease, and neurological conditions, and in the design and development of better medicines for treating these afflictions.
Collapse
Affiliation(s)
- Amit Kumar
- Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA; Antibody Discovery and Protein Engineering, MedImmune LLC, One MedImmune Way, Gaithersburg, MD, USA; Biotechnology Core Laboratory, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA
| | | | | | | | | |
Collapse
|
30
|
Buchanan A, Clementel V, Woods R, Harn N, Bowen MA, Mo W, Popovic B, Bishop SM, Dall'Acqua W, Minter R, Jermutus L, Bedian V. Engineering a therapeutic IgG molecule to address cysteinylation, aggregation and enhance thermal stability and expression. MAbs 2013; 5:255-62. [PMID: 23412563 PMCID: PMC3893235 DOI: 10.4161/mabs.23392] [Citation(s) in RCA: 52] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023] Open
Abstract
Antibodies can undergo a variety of covalent and non-covalent degradation reactions that have adverse effects on efficacy, safety, manufacture and storage. We had identified an antibody to Angiopoietin 2 (Ang2 mAb) that neutralizes Ang2 binding to its receptor in vitro and inhibits tumor growth in vivo. Despite favorable pharmacological activity, the Ang2 mAb preparations were heterogeneous, aggregated rapidly and were poorly expressed. Here, we report the engineering of the antibody variable and constant domains to generate an antibody with reduced propensity to aggregate, enhanced homogeneity, 11°C elevated T(m), 26-fold improved level of expression and retained activity. The engineered molecule, MEDI-3617, is now compatible with the large scale material supply required for clinical trials and is currently being evaluated in Phase 1 in cancer patients. This is the first report to describe the stability engineering of a therapeutic antibody addressing non canonical cysteine residues and the design strategy reported here is generally applicable to other therapeutic antibodies and proteins.
Collapse
|
31
|
Ward E, Mittereder N, Kuta E, Sims GP, Bowen MA, Dall'Acqua W, Tedder T, Kiener P, Coyle AJ, Wu H, Jallal B, Herbst R. A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo. Br J Haematol 2011; 155:426-37. [PMID: 21902688 DOI: 10.1111/j.1365-2141.2011.08857.x] [Citation(s) in RCA: 61] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Human cluster of differentiation (CD) antigen 19 is a B cell-specific surface antigen and an attractive target for therapeutic monoclonal antibody (mAb) approaches to treat malignancies of B cell origin. MEDI-551 is an affinity-optimized and afucosylated CD19 mAb with enhanced antibody-dependent cellular cytotoxicity (ADCC). The results from in vitro ADCC assays with Natural Killer cells as effector cells, demonstrate that MEDI-551 is effective at lower mAb doses than rituximab with multiple cell lines as well as primary chronic lymphocytic leukaemia and acute lymphoblastic leukaemia samples. Targeting CD19 with MEDI-551 was also effective in several severe combined immunodeficiency lymphoma models. Furthermore, the combination of MEDI-551 with rituximab resulted in prolonged suppression of tumour growth, demonstrating that therapeutic mAbs with overlapping effector function can be combined for greater tumour growth inhibition. Together, the data demonstrate that MEDI-551 has potent antitumour activity in preclinical models of B cell malignancies. The results also suggest that the combination of the ADCC-enhanced CD19 mAb with an anti-CD20 mAb could be a novel approach for the treatment of B cell lymphomas.
Collapse
Affiliation(s)
- Elizabeth Ward
- Department of Research, MedImmune, LLC, Gaithersburg, MD 20787, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Herbst R, Wang Y, Gallagher S, Mittereder N, Kuta E, Damschroder M, Woods R, Rowe DC, Cheng L, Cook K, Evans K, Sims GP, Pfarr DS, Bowen MA, Dall'Acqua W, Dall'Aqua W, Shlomchik M, Tedder TF, Kiener P, Jallal B, Wu H, Coyle AJ. B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody. J Pharmacol Exp Ther 2010; 335:213-22. [PMID: 20605905 DOI: 10.1124/jpet.110.168062] [Citation(s) in RCA: 100] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
The pan B-cell surface antigen CD19 is an attractive target for therapeutic monoclonal antibody (mAb) approaches. We have generated a new afucosylated anti-human (hu)CD19 mAb, MEDI-551, with increased affinity to human FcγRIIIA and mouse FcγRIV and enhanced antibody-dependent cellular cytotoxicity (ADCC). During in vitro ADCC assays with B-cell lines, MEDI-551 is effective at much lower mAb concentrations than the fucosylated parental mAb anti-CD19-2. Furthermore, the afucosylated CD19 mAb MEDI-551 depleted B cells from normal donor peripheral blood mononuclear cell samples in an autologous ADCC assay, as well as blood and tissue B cells in human CD19/CD20 double transgenic (Tg) mice at lower concentrations than that of the positive control mAb rituximab. In huCD19/CD20 Tg mice, both macrophage-mediated phagocytosis and complement-dependent cytotoxicity contribute to depletion with rituximab; MEDI-551 did not require complement for maximal B-cell depletion. Furthermore, extended B-cell depletion from the blood and spleen was achieved with MEDI-551, which is probably explained by bone marrow B-cell depletion in huCD19/CD20 Tg mice relative to the control mAb rituximab. In summary, MEDI-551 has potent B-cell-depleting activity in vitro and in vivo and may be a promising new approach for the treatment of B-cell malignancies and autoimmune diseases.
Collapse
Affiliation(s)
- Ronald Herbst
- Department of Research, Respiratory, Inflammation, and Autoimmunity, MedImmune, LCC, Gaithersburg, MD 20787, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Affiliation(s)
- Michael A Bowen
- Division of Abdominal Imaging, Department of Radiology, Emory University School of Medicine, 1364 Clifton Rd NE, Atlanta, GA 30322, USA
| | | | | |
Collapse
|
34
|
Abidi SMA, Saifullah MK, Zafiropulos MD, Kaput C, Bowen MA, Cotton C, Singer NG. CD166 expression, characterization, and localization in salivary epithelium: implications for function during sialoadenitis. J Clin Immunol 2006; 26:12-21. [PMID: 16418799 DOI: 10.1007/s10875-006-7119-6] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2005] [Accepted: 06/30/2005] [Indexed: 11/24/2022]
Abstract
CD166 is an Ig superfamily molecule that binds homotypically to itself and heterotypically to CD6. Interactions between CD6 and CD166 are important during immune development and in alloreactivity. CD166 is expressed at increased levels in selected cancers and in rheumatoid arthritis synovium. Knowledge that CD166 was expressed in normal human salivary epithelium led to these studies of CD166 and CD6 in diseased mouse salivary glands, that resemble pathology seen in the human disease, Sjögren's syndrome. We showed that in mouse salivary epithelium CD166 was expressed but that expression of CD166 did not necessarily predict its function. Recombinant soluble CD6-Ig bound to CD6 ligands (CD6L) on transformed and freshly isolated salivary epithelial cells. Cross-blocking studies showed that binding of CD6-Ig to salivary epithelium was in part dependent on CD166, but that CD6-Ig binding may also involve additional CD6L. Binding of CD6-Ig was sensitive to trypsin digestion but resistant to digestion by collagenase and sialidase. Anti-CD166 ab precipitated CD166 from salivary epithelium pre- and post-treatment with the pro-inflammatory cytokine IFN-gamma. In contrast CD6-Ig only precipitated CD166 from IFN-gamma treated cells. More extensive colocalization between CD166 and the actin cytoskeleton was observed in sialoadenitis epithelium compared to control. We conclude that during sialoadenitis, CD166 undergoes a gain of function, resulting in closer association with the actin cytoskeleton and increased capacity to bind CD6. We suggest that altered CD166 function may contribute to the pro-inflammatory milieu during sialoadenitis seen in Sjögren's syndrome.
Collapse
Affiliation(s)
- Syed M A Abidi
- Department of Pediatrics, CASE School of Medicine and Rainbow Babies and Children's Hospital, Cleveland, Ohio 44106, USA
| | | | | | | | | | | | | |
Collapse
|
35
|
Ramos-Casals M, Font J, García-Carrasco M, Calvo J, Places L, Padilla O, Cervera R, Bowen MA, Lozano F, Ingelmo M. High circulating levels of soluble scavenger receptors (sCD5 and sCD6) in patients with primary Sjögren's syndrome. Rheumatology (Oxford) 2001; 40:1056-9. [PMID: 11561119 DOI: 10.1093/rheumatology/40.9.1056] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
OBJECTIVE To determine the existence of circulating levels of soluble scavenger receptors (sCD5 and sCD6) in patients with primary Sjögren's syndrome (SS), and to analyse the correlation with clinical and immunological features of SS. METHODS Ninety consecutive patients with primary SS were studied. All patients fulfilled four or more of the European diagnostic criteria for SS. sCD5 and sCD6 levels were determined using a specific enzyme-linked immunosorbent assay (ELISA) developed in our laboratory. RESULTS Detectable levels of sCD5 were found in 39 (43%) SS patients. The mean+/-standard error values of sCD5 were 3.5+/-0.5 ng/ml for patients with SS and 1.9+/-0.1 ng/ml for healthy blood donors (P<0.001). We found higher levels of sCD5 in patients with hypocomplementaemia (6.5 vs 3.5 ng/ml, P=0.03) and cryoglobulinaemia (6.9 vs 2.6 ng/ml, P=0.001). On the other hand, detectable levels of sCD6 were found in 60 (67%) SS patients. The mean+/-standard error values of sCD6 were 25.5+/-7.8 ng/ml in SS patients and 5.27+/-1.40 ng/ml in healthy blood donors (P=0.01). When the sCD6 levels were compared according to the presence or absence of immunological features, patients with cryoglobulinaemia showed higher levels of circulating sCD6 (77.3 vs 17 ng/ml, P=0.01) than those without cryoglobulinaemia. CONCLUSION Patients with primary SS showed higher levels of circulating sCD5 and sCD6 when compared with controls. Moreover, the existence of some immunological features (hypocomplementaemia and cryoglobulinaemia) was associated with high levels of both soluble scavenger receptors. These facts may reflect an enhanced lymphocytic activation in patients with primary SS.
Collapse
Affiliation(s)
- M Ramos-Casals
- Systemic Autoimmune Diseases Unit and. Department of Immunology, Hospital Clínic, Department of Medicine, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), School of Medicine, University of Barcelona, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Lozano F, Simarro M, Calvo J, Vilà JM, Padilla O, Bowen MA, Campbell KS. CD5 signal transduction: positive or negative modulation of antigen receptor signaling. Crit Rev Immunol 2001; 20:347-58. [PMID: 11100806] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/18/2023]
Abstract
The CD5 lymphocyte surface glycoprotein is a coreceptor involved in the modulation of antigen-specific receptor-mediated activation and differentiation signals. Although first considered a costimulatory molecule in mature peripheral T cells, recent studies of CD5-/- mice have opened the possibility that CD5 may also mediate inhibitory signals that attenuate TCR/CD3- and BCR-mediated triggering in thymocytes and a subgroup of B cells (B-1a cells), respectively. The ultimate molecular basis for these differential modulatory properties of CD5, depending on the context of lymphocyte subset and differentiation stage, are presently unknown and are an issue of current intensive investigation. Here, we review recent reports, both contradictory and complementary, focused on CD5-mediated molecular intracellular signaling events that could provide the basis for its immunomodulatory properties.
Collapse
Affiliation(s)
- F Lozano
- Servei d'Immunologia, Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic, Villarroel, Barcelona, Spain
| | | | | | | | | | | | | |
Collapse
|
37
|
Bowen MA, Aruffo AA, Bajorath J. Cell surface receptors and their ligands: in vitro analysis of CD6-CD166 interactions. Proteins 2000; 40:420-8. [PMID: 10861932] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
Abstract
CD6 is a cell surface receptor belonging to the scavenger receptor cysteine-rich (SRCR) protein superfamily (SRCRSF). It specifically binds activated leukocyte cell adhesion molecule (ALCAM, CD166), a member of the immunoglobulin (Ig) superfamily (IgSF). CD166 was among the first molecules identified as a ligand for an SRCRSF receptor, and the CD6-CD166 interaction was the first interaction characterized involving SRCRSF and IgSF proteins. We focus here on what has been learned about the specifics of the CD6-CD166 interaction from in vitro analysis. The studies are thought to provide an instructive example for the analysis of interactions between single-path transmembrane cell surface proteins. Using soluble recombinant forms, the extracellular binding domains of receptor and ligand have been identified and characterized in a variety of assay systems. Both CD6 and CD166 have been subjected to intense mutagenesis and monoclonal antibody (mAb) binding studies and residues critical for their interaction have been identified. The availability of structural prototypes of both superfamilies has made it possible to map the binding site in CD166 and, more recently, in CD6 and compare these regions to epitopes of mAbs that block, or do not block, the interaction. In addition, the molecular basis of observed cross-species receptor-ligand interactions could be rationalized. These studies illustrate the value of structural templates for the interpretation of sequence and mutagenesis analyses. Proteins 2000;40:420-428.
Collapse
MESH Headings
- Activated-Leukocyte Cell Adhesion Molecule/genetics
- Activated-Leukocyte Cell Adhesion Molecule/metabolism
- Amino Acid Sequence
- Antigens, CD/genetics
- Antigens, CD/metabolism
- Antigens, Differentiation, T-Lymphocyte/genetics
- Antigens, Differentiation, T-Lymphocyte/metabolism
- Binding Sites
- Ligands
- Membrane Proteins
- Models, Molecular
- Molecular Sequence Data
- Protein Binding
- Receptors, Immunologic/genetics
- Receptors, Immunologic/metabolism
- Receptors, Lipoprotein
- Receptors, Scavenger
- Recombinant Proteins/metabolism
- Scavenger Receptors, Class B
Collapse
Affiliation(s)
- M A Bowen
- Bristol-Myers Squibb Pharmaceutical Research Institute, Immunology, Inflammation, and Pulmonary Drug Discovery, Princeton, New Jersey, USA
| | | | | |
Collapse
|
38
|
|
39
|
Pospisil R, Silverman GJ, Marti GE, Aruffo A, Bowen MA, Mage RG. CD5 is A potential selecting ligand for B-cell surface immunoglobulin: a possible role in maintenance and selective expansion of normal and malignant B cells. Leuk Lymphoma 2000; 36:353-65. [PMID: 10674908 DOI: 10.3109/10428190009148857] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Although the function of CD5 on B cells is unknown, previous studies suggested that CD5 interaction with V(H) framework regions of surface immunoglobulins (Igs) may contribute to survival and expansion of B cells. Here we used B-chronic lymphocytic leukemia (B-CLL) cells and transformed B-cell lines from normal and B-CLL patients to study CD5-Ig interactions. Immobilized Ig binds and permits isolation of CD5 from lysates of CD5-expressing cell lines. Immunoglobulins or Fab fragments of different V(H) families varied in their effectiveness as inhibitors of anti-CD5 staining of CLL cells, appendix and tonsil tissue sections. Human Ig also binds to purified recombinant CD5. We show here for the first time that the unconventional Ig-CD5 interaction maps to the extracellular CD5-D2 domain whereas conventional epitopes recognized by anti-CD5 antibodies are localized in the D1 domain of CD5. We propose that interactions of VH framework regions with CD5 as a ligand may maintain, select or expand normal, autoimmune or transformed B cells and also contribute to skewing of the normal V(H) repertoire.
Collapse
Affiliation(s)
- R Pospisil
- Laboratory of Immunology, NIAID, NIH, Bethesda, MD 20892, USA
| | | | | | | | | | | |
Collapse
|
40
|
Lozano F, Simarro M, Calvo J, Vila JM, Padilla O, Bowen MA, Campbell KS. CD5 Signal Transduction: Positive or Negative Modulation of Antigen Receptor Signaling. ACTA ACUST UNITED AC 2000. [DOI: 10.1615/critrevimmunol.v20.i4.30] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
41
|
Calvo J, Padilla O, Places L, Vigorito E, Vilà JM, Vilella R, Milà J, Vives J, Bowen MA, Lozano F. Relevance of individual CD5 extracellular domains on antibody recognition, glycosylation and co-mitogenic signalling. Tissue Antigens 1999; 54:16-26. [PMID: 10458319 DOI: 10.1034/j.1399-0039.1999.540102.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
CD5 is a type I glycoprotein which modulates T- and B-cell receptor-mediated signals and is expressed by thymocytes, mature T cells and a subset of mature B cells. The extracellular region of CD5 is composed of three scavenger receptor cysteine-rich domains (D1, D2, D3) for which only limited functional and structural data are available. Using cell transfectants expressing ectodomain-deficient CD5 molecules or CD5 immunoglobulin fusion proteins, we analysed individual CD5 domains with respect to monoclonal antibody binding specificity, glycosylation, and co-mitogenic signalling. Our results show the presence of N-linked oligosaccharides on D1 and D2, but not on D3. D1, the most amino-terminal domain, is predicted to be the most appropriately placed domain for an interaction with a ligand. This domain is recognised by a large panel of well characterised CD5 mAbs, reflecting its higher immunogenicity. In an attempt to develop mAbs with specificity for the more conserved membrane-proximal domains, we generated a unique mAb, named 83-C4, whose binding mapped to D3. Co-stimulatory studies revealed no significant differences between anti-D1 and anti-D3 mAbs. The high interspecies conservation of D3 implies a conserved role of this domain in CD5 function and the 83-C4 mAb promises to be a valuable tool in exploring this.
Collapse
Affiliation(s)
- J Calvo
- Servei d'Immunologia, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clínic, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Abstract
CD5, a member of the scavenger receptor cysteine-rich (SRCR) receptor family, plays a role in the thymocyte maturation, T cell activation and T cell-antigen-presenting cell interactions. To date only CD5 ligands (CD5L) compatible with a T-B co-stimulatory role have been described (CD72, gp40-80 and IgV(H) framework region) so the existence of alternative CD5L involved in other aspects of T cell biology warrants further exploration. Here we characterize the cell binding properties of a recombinant soluble human CD5 extracellular domain glycoprotein (rsCD5). In contrast to previously characterized ligands, this molecule binds to a broadly distributed cell surface receptor expressed on monocytes, lymphocytes and various cell lines of lymphoid, myelomonocytic and epithelial origin. The cell binding of rsCD5 is divalent cation independent and inhibited by high molar concentrations of certain monosaccharides. Both human CD5 Ig fusion proteins and a natural soluble CD5 form (present in human serum and resulting from proteolytic cleavage following lymphocyte activation) reproduce the cell binding pattern of rsCD5 and block its binding in a competitive form. The involvement of the most N-terminal CD5 SRCR domains (D1 and D2) in binding is deduced from competition cell binding assays with CD5 Ig fusion proteins. These results imply a novel CD5/CD5L interaction model recalling some aspects of the interaction of CD6 with activated leukocyte cell adhesion molecule (ALCAM).
Collapse
Affiliation(s)
- J Calvo
- Servei d'Immunologia, Institut D'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clínic, Barcelona, Spain
| | | | | | | | | | | | | |
Collapse
|
43
|
Perez-Villar JJ, Whitney GS, Bowen MA, Hewgill DH, Aruffo AA, Kanner SB. CD5 negatively regulates the T-cell antigen receptor signal transduction pathway: involvement of SH2-containing phosphotyrosine phosphatase SHP-1. Mol Cell Biol 1999; 19:2903-12. [PMID: 10082557 PMCID: PMC84084 DOI: 10.1128/mcb.19.4.2903] [Citation(s) in RCA: 145] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
The negative regulation of T- or B-cell antigen receptor signaling by CD5 was proposed based on studies of thymocytes and peritoneal B-1a cells from CD5-deficient mice. Here, we show that CD5 is constitutively associated with phosphotyrosine phosphatase activity in Jurkat T cells. CD5 was found associated with the Src homology 2 (SH2) domain containing hematopoietic phosphotyrosine phosphatase SHP-1 in both Jurkat cells and normal phytohemagglutinin-expanded T lymphoblasts. This interaction was increased upon T-cell receptor (TCR)-CD3 cell stimulation. CD5 co-cross-linking with the TCR-CD3 complex down-regulated the TCR-CD3-increased Ca2+ mobilization in Jurkat cells. In addition, stimulation of Jurkat cells or normal phytohemagglutinin-expanded T lymphoblasts through TCR-CD3 induced rapid tyrosine phosphorylation of several protein substrates, which was substantially diminished after CD5 cross-linking. The CD5-regulated substrates included CD3zeta, ZAP-70, Syk, and phospholipase Cgammal but not the Src family tyrosine kinase p56(lck). By mutation of all four CD5 intracellular tyrosine residues to phenylalanine, we found the membrane-proximal tyrosine at position 378, which is located in an immunoreceptor tyrosine-based inhibitory (ITIM)-like motif, crucial for SHP-1 association. The F378 point mutation ablated both SHP-1 binding and the down-regulating activity of CD5 during TCR-CD3 stimulation. These results suggest a critical role of the CD5 ITIM-like motif, which by binding to SHP-1 mediates the down-regulatory activity of this receptor.
Collapse
Affiliation(s)
- J J Perez-Villar
- Immunology and Inflammation Drug Discovery, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543, USA.
| | | | | | | | | | | |
Collapse
|
44
|
Bowen MA, Aruffo A. Adhesion molecules, their receptors, and their regulation: analysis of CD6-activated leukocyte cell adhesion molecule (ALCAM/CD166) interactions. Transplant Proc 1999; 31:795-6. [PMID: 10083342 DOI: 10.1016/s0041-1345(98)01773-4] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
- M A Bowen
- Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ 08543, USA.
| | | |
Collapse
|
45
|
Kobarg J, Schnittger S, Fonatsch C, Lemke H, Bowen MA, Buck F, Hansen HP. Characterization, mapping and partial cDNA sequence of the 57-kD intracellular Ki-1 antigen. Exp Clin Immunogenet 1998; 14:273-80. [PMID: 9523163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
A novel antigen was identified by the cross-reactivity of the anti-CD30 antibody Ki-1. This 57-kD intracellular Ki-1 antigen (Ki-1/57) is induced upon activation of leukocytes and is transported to the nuclear compartment. We describe the partial cloning and sequencing of the Ki-1/57 cDNA from a lambda gt 11-cDNA library derived from the Hodgkin-analogous cell line L540. New monoclonal antibodies were produced against the recombinant Ki-1/57 protein fragment which were used to confirm that the Ki-1/57 antigen is associated with kinase activity and is expressed in a variety of tumor cell lines and in activated but not resting leukocytes. The Ki-1/57 gene was mapped to the bands 9q22.3-31 of human chromosome 9. This is an area which appears to be associated with secondary chromosomal aberrations in acute myeloid leukemias.
Collapse
Affiliation(s)
- J Kobarg
- Bristol-Myers Squibb, Pharmaceutical Research Institute, Princeton, N.J. 08543-4000, USA.
| | | | | | | | | | | | | |
Collapse
|
46
|
Kobarg J, Whitney GS, Palmer D, Aruffo A, Bowen MA. Analysis of the tyrosine phosphorylation and calcium fluxing of human CD6 isoforms with different cytoplasmatic domains. Eur J Immunol 1997; 27:2971-80. [PMID: 9394826 DOI: 10.1002/eji.1830271133] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
CD6 is a cell surface glycoprotein that functions both as a co-stimulatory and adhesion receptor on T cells. Recently we have described CD6 isoforms (CD6a, b, c, d, e) that arise via alternative splicing of exons encoding the cytoplasmic region of the molecule. CD6 becomes phosphorylated on tyrosine (Tyr) residues following stimulation through the T cell receptor (TCR) complex. Since the phosphorylation of Tyr residues renders some cell surface receptors competent for interactions with proteins of intracellular signaling pathways, we wanted to determine which region(s) and residues in the cytoplasmic domain of CD6 were important for phosphorylation on Tyr residues. We engineered and stably expressed chimeric receptors that consisted of the extracellular region of mouse CD6 and the cytoplasmic regions of either naturally occurring isoforms of human CD6, truncated proteins, or point mutants. We were able to demonstrate that of the nine Tyr residues in the cytoplasmic domain of the largest isoform CD6a, the two C-terminal Tyr residues (Tyr 629/662) are critical for the phosphorylation of CD6 following TCR cross-linking. Isoform CD6e, which is missing a region that contains two proline-rich motifs, is not phosphorylated. We further analyzed the ability of the different CD6 isoforms and truncated receptors to mobilize intracellular calcium after CD6/TCR co-ligation. All CD6 isoforms, including CD6e, as well as the truncation mutant delta 555, which is missing approximately the C-terminal half of the cytoplasmic domain, are able to increase Ca2+ influx. Taken together, these results suggest that the region of CD6 which is critical for Ca2+ mobilization is located N-terminal from amino acid 555 and is therefore different from the region located at the C terminus of CD6, which is necessary for tyrosine phosphorylation.
Collapse
MESH Headings
- Amino Acid Sequence
- Amino Acid Substitution/genetics
- Animals
- Antigens, CD/chemistry
- Antigens, CD/genetics
- Antigens, CD/metabolism
- Antigens, Differentiation, T-Lymphocyte/chemistry
- Antigens, Differentiation, T-Lymphocyte/genetics
- Antigens, Differentiation, T-Lymphocyte/metabolism
- Calcium/metabolism
- Cell Culture Techniques
- Cytoplasm/chemistry
- Cytoplasm/immunology
- Cytoplasm/metabolism
- Humans
- Isomerism
- Jurkat Cells
- Mice
- Molecular Sequence Data
- Mutagenesis, Site-Directed
- Phosphorylation
- Point Mutation
- Protein Structure, Tertiary
- Recombinant Fusion Proteins/biosynthesis
- Tyrosine/genetics
- Tyrosine/metabolism
Collapse
Affiliation(s)
- J Kobarg
- Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, USA.
| | | | | | | | | |
Collapse
|
47
|
Abstract
The scavenger receptor cysteine-rich (SRCR) superfamily, which includes proteins expressed by leukocytes, can be subdivided into groups A and B. Group B contains the lymphocyte cell-surface receptor CD6. This article reviews recent progress in understanding the interaction between CD6 and its ligand, activated leukocyte cell adhesion molecule (ALCAM). Analysis of the CD6-ALCAM interaction may help to understand how other SRCR domains bind to their ligands.
Collapse
MESH Headings
- Activated-Leukocyte Cell Adhesion Molecule
- Amino Acid Sequence
- Animals
- Antigens, CD/immunology
- Antigens, Differentiation, T-Lymphocyte/immunology
- Cell Adhesion Molecules/immunology
- Glycoproteins/immunology
- Humans
- Ligands
- Membrane Proteins
- Models, Molecular
- Molecular Sequence Data
- Receptors, Cell Surface/chemistry
- Receptors, Cell Surface/genetics
- Receptors, Cell Surface/immunology
- Receptors, Immunologic
- Receptors, Lipoprotein
- Receptors, Scavenger
- Scavenger Receptors, Class B
- Sequence Homology, Amino Acid
Collapse
Affiliation(s)
- A Aruffo
- Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, WA 98121, USA.
| | | | | | | | | | | | | |
Collapse
|
48
|
Whalen RL, Cai C, Thompson LM, Sarrasin MJ, Dempsey DJ, Bowen MA. An infection inhibiting urinary catheter material. ASAIO J 1997; 43:M842-7. [PMID: 9360165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
Catheter associated bacteriuria is a common infection in hospitals and nursing homes. An infection inhibiting catheter material for fabricating urinary catheters is being developed. The material consists of silicone rubber elastomer compounded with chlorhexidene gluconate (CHG) matrix. The antibiotic is released in sustained fashion over at least 4 weeks. A method was established for adding CHG to silicone rubber. To protect the CHG, it is suspended in a water soluble wax that also modulates CHG release from the elastomer. It was found that CHG is randomly dispersed in the elastomer and that the primary release mechanism is by diffusion. The antibacterial activity of the material with a range of 0.1 to 5% CHG by weight was examined using in vitro zone inhibition testing. The new material demonstrated significant inhibitory activity against three pathogens tested (Escherichia coli, Proteus mirabilis and Staphylococcus epidermidis.). The release rate of CHG was measured in vitro using high performance liquid chromatography (HPLC). With 5% CHG loading, the antibiotic was released at a steady rate of approximately 8.4 mg/cm2/day for periods extending beyond 4 weeks. This new material for urinary catheters has the potential to provide protection against infection and surface colonization.
Collapse
Affiliation(s)
- R L Whalen
- Whalen Biomedical Incorporated Cambridge, Massachusetts 02138, USA
| | | | | | | | | | | |
Collapse
|
49
|
Abstract
CD6 belongs to the scavenger receptor cysteine-rich protein superfamily (SRCRSF), which includes a large number of cell surface proteins. The extracellular region of CD6 is composed of three SRCR domains. The membrane proximal SRCR domain of CD6 (CD6D3) specifically binds activated leukocyte cell adhesion molecule (ALCAM), a cell surface protein which is a member of the immunoglobulin superfamily (IgSF). CD6-ligand interactions have been implicated in immune cell adhesion, T cell maturation and the regulation of T cell activation. We tested 13 CD6D3 mutant proteins for binding to ALCAM and a panel of conformationally sensitive anti-CD6D3 monoclonal antibodies (mAbs). CD6D3 residues were classified according to their importance for structural integrity and ligand binding. The results were analyzed in the light of SRCR domain sequence comparison. A number of residues critical for ligand binding or important for structural integrity cluster in the C-terminal region of CD6D3 which is not conserved in other SRCR proteins.
Collapse
MESH Headings
- Activated-Leukocyte Cell Adhesion Molecule
- Amino Acid Sequence
- Animals
- Antibodies, Monoclonal/immunology
- Antigens, CD/chemistry
- Antigens, CD/genetics
- Antigens, CD/immunology
- Antigens, CD/metabolism
- Antigens, Differentiation, T-Lymphocyte/chemistry
- Antigens, Differentiation, T-Lymphocyte/genetics
- Antigens, Differentiation, T-Lymphocyte/immunology
- Antigens, Differentiation, T-Lymphocyte/metabolism
- Biosensing Techniques
- DNA Mutational Analysis
- Enzyme-Linked Immunosorbent Assay
- Glycoproteins/genetics
- Glycoproteins/metabolism
- Humans
- Ligands
- Membrane Proteins
- Molecular Sequence Data
- Mutagenesis, Site-Directed
- Protein Binding
- Receptors, Cell Surface/chemistry
- Receptors, Cell Surface/genetics
- Receptors, Cell Surface/immunology
- Receptors, Cell Surface/metabolism
- Receptors, Immunologic
- Receptors, Lipoprotein
- Receptors, Scavenger
- Recombinant Fusion Proteins/metabolism
- Scavenger Receptors, Class B
- Sequence Homology, Amino Acid
Collapse
Affiliation(s)
- J E Skonier
- Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, WA 98121, USA
| | | | | | | | | | | |
Collapse
|
50
|
Abstract
CD6 and its ligand activated leukocyte cell adhesion molecule (ALCAM, CD166) have been detected on various immune cells and in the brain. CD6-ligand interactions have been implicated in the regulation of T cell function. ALCAM shares the same extracellular domain organization and significant sequence homology with the chicken neural adhesion molecule BEN. Although ALCAM's CD6 binding site is only partially conserved in BEN, CD6 specifically binds BEN, albeit with approximately 10-fold lower avidity than ALCAM. Differences in binding avidity are not detected when ALCAM and BEN fusion proteins containing the full-length extracellular regions are tested. Homotypic interactions between full-length forms are likely to account for these observations. The identified cross-species interaction between CD6 and BEN suggests that CD6-ligand interactions are highly conserved.
Collapse
Affiliation(s)
- J E Skonier
- Bristol-Myers Squibb Pharmaceutical Research Institute (BMS-PRI), Seattle, Washington 98121, USA
| | | | | | | |
Collapse
|